Intravitreal Injections (Avastin, Lucentis, Macugen, Razumab, Ozurdex)
- Home
- Intravitreal Injections (Avastin, Lucentis, Macugen, Razumab, Ozurdex)
Intravitreal Injections (Avastin, Lucentis, Macugen, Razumab, Ozurdex)
Intravitreal injections have revolutionized the treatment of various retinal conditions, offering a minimally invasive approach to delivering medication directly into the eye.
Advantages of Intravitreal Injections:
- Targeted Treatment: Intravitreal injections deliver medication directly into the vitreous gel of the eye, allowing for precise and concentrated treatment of specific retinal conditions such as age-related macular degeneration (AMD), diabetic retinopathy, or retinal vein occlusion.
- Minimally Invasive: Compared to surgical procedures, intravitreal injections are relatively quick, simple, and require only a local anesthetic. They are performed in an outpatient setting, reducing the need for hospitalization.
- Effective Results: Intravitreal injections have shown significant efficacy in improving or stabilizing vision, reducing macular edema, and preventing disease progression in various retinal conditions.
Types of Intravitreal Injections:
- Avastin (Bevacizumab): Originally developed as a cancer medication, Avastin is commonly used off-label for the treatment of various retinal conditions. It inhibits the growth of abnormal blood vessels and reduces macular edema.
- Lucentis (Ranibizumab): Specifically designed for intravitreal use, Lucentis is FDA-approved for treating AMD, diabetic macular edema, and macular edema due to retinal vein occlusion. It works by blocking vascular endothelial growth factor (VEGF).
- Macugen (Pegaptanib Sodium): Macugen is used for the treatment of neovascular (wet) AMD. It selectively targets a specific form of VEGF, reducing abnormal blood vessel growth and leakage.
- Razumab (Biosimilar Ranibizumab): A biosimilar to Lucentis, Razumab offers a more cost-effective alternative for the treatment of retinal conditions. It has similar efficacy and safety profiles.
- Ozurdex (Dexamethasone Implant): Ozurdex is a biodegradable implant that releases a corticosteroid (dexamethasone) into the eye. It is used for the treatment of macular edema associated with retinal vein occlusion or uveitis.